Products
TearRestore launches OneDrop for daily dry eye care
Artificial tear is formulated with a preservative-free-based nanoemulsion engineered to mimic and reinforce all three layers of the natural tear film.
Products
Harrow unveils new direct-to-prescriber cash-pay program for branded products
Initial rollout of the PharmaPack kits includes FDA-approved NEVANAC, MAXITROL, or TOBRADEX ST for ImprimisRx customers in five states.
Research
Lutein shows potential as myopia management supplement
Preliminary RCT data highlights preservation of choroidal thickness in children taking lutein supplements.
Business
iCare and MediWhale partner on AI-based CVD retinal imaging
Strategic collaboration would integrate iCare’s DRSplus fundus imaging system with the autonomous Mr. Noon CVD software to predict patients’ CVD risk.
Products
FDA approves expanded age indication for STAAR's EVO/EVO+ Visian ICLs
U.S. age indication now includes patients aged 21 to 60 years old, making nearly 8 million refractive patients eligible for implantable collamer lens implantation.
Products
Alcon launches TOTAL30 Multifocal for Astigmatism toric contact lens
Designed for astigmatic presbyopes, the latest TOTAL30 is the only monthly MF toric lens featuring proprietary Water Gradient Technology.
Pipeline
Ocular Therapeutix reports positive phase 3 SOL-1 superiority data for wet AMD
AXPAXLI is the first and only novel drug to demonstrate superiority to an approved anti-VEGF treatment in an FDA-aligned wet AMD study.
Pipeline
Nicox reports positive pre-NDA FDA meeting for IOP-lowering drop
NO-donating bimatoprost formulation remains on track for a summer 2026 new drug application submission.
Pipeline
FDA clears Cloudbreak Pharma's IND for phase 2 presbyopia drop trials
Clearance green lights advancement of CBT-199, an ophthalmic emulsion with a proprietary, water-free formulation and parasympathomimetic miotic agent.
Products
FDA approves DifGen's fluorometholone 0.1% complex generic for ocular inflammation
Prescription-based corticosteroid suspension is the second generic of AbbVie’s FML 0.1% to receive regulatory approval.
Research
Could RAR determine cataract risk?
Cost-effective biomarker emerges as potential tool for risk assessment and early prevention in cataract patients.
Research
Dual GIP-GLP-1 RA shows superior efficacy in lowering POAG, OHT risk
Tirzepatide consistently reduced the risk of glaucomatous disease compared to GLP-1 RAs, even among high-risk patients.
Legal
Samsung Biopeis and Regeneron settle EYLEA biosimilar US patent dispute
Settlement and license agreement clears the way for a January 2027 commercial launch of OPUVIZ 2 mg (aflibercept-yszy) injection.
Pipeline
Pandorum Tech raises $18M to expand operations for bioengineered cornea
Financing to advance biotech’s ‘liquid-based cornea’ Kuragenx, an eye drop bioengineered to revert an ulcerative cornea to its healthy state in less than 1 year.
Business
Arctic Vision acquires MDCO Technology's ophthalmic device business
Integration will support global ophthalmic pipeline expansion addressing significant unmet needs in retinal disease, dry eye, and ocular neuroprotection.
Research
Iron overload may increase glaucoma risk
Study proposes that systemic iron dysregulation is a modifiable risk factor for glaucomatous disease.
Business
VIEW Optometry launches to support independent practices
Doctor-founded alliance allows private practice optometrists to maintain ownership while benefiting from a network of tools and resources.
Pipeline
4DMT completes enrollment for phase 3 wet AMD gene therapy trial
4FRONT-1 study is evaluating 4D-150 as a single, low-dose IVT injection among treatment-naïve wet AMD patients; topline data expected in H1 2027.
Research
Seasonal variations play major role in CSC development
Observed increased incidence of CSC in spring and autumn provide potential insights into the disease’s pathogenesis.
Products